What is the dose of Avil (promethazine) in pediatric anaphylaxis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Epinephrine, Not Promethazine (Avil), is the First-Line Treatment for Pediatric Anaphylaxis

Epinephrine, not promethazine (Avil), is the recommended first-line treatment for pediatric anaphylaxis, with a dose of 0.01 mg/kg up to 0.3 mg administered intramuscularly into the lateral thigh. 1

Correct Medication for Anaphylaxis

  • Epinephrine is the primary medical therapy for anaphylaxis and must be administered promptly 1
  • Antihistamines like promethazine (Avil) should not be substituted for epinephrine as they do not reverse anaphylaxis 2, 3
  • H1-antihistamines may be used as adjunctive treatment only after epinephrine administration 2

Epinephrine Dosing in Pediatric Anaphylaxis

  • The recommended dose is 0.01 mg/kg up to a maximum of 0.3 mg in prepubertal children 1, 2
  • For auto-injectors, use 0.15 mg for children weighing 10-25 kg and 0.3 mg for children weighing ≥25 kg 1, 2
  • Intramuscular injection into the lateral thigh (vastus lateralis muscle) is the preferred route 1

Administration Considerations

  • Epinephrine reaches peak plasma concentration in approximately 8 ± 2 minutes when injected intramuscularly in the vastus lateralis 1
  • If needed, a second dose can be administered 5-15 minutes after the first dose if symptoms persist 1, 2
  • 6-19% of pediatric patients treated with epinephrine require a second dose 1

Special Populations and Considerations

  • For infants weighing less than 15 kg, in the absence of a suitable alternative, the 0.15 mg auto-injector is recommended despite being higher than the calculated dose 3
  • The Canadian Society of Allergy and Immunology recommends using the 0.15 mg auto-injector for children weighing less than 15 kg, as adverse effects are expected to be mild and transient compared to the risk of not receiving epinephrine 3
  • For infants, drawing up the dose from a vial is an alternative but presents challenges in accuracy and time delay 1

Important Caveats

  • Delayed administration of epinephrine is associated with poor outcomes and increased risk of fatality 2
  • Intravenous administration carries risks of dilution errors and dosing errors and should be reserved for severe cases not responding to IM epinephrine or in hospital settings 1
  • Auto-injector needle length may be too long for some infants (risk of intraosseous injection) and too short for some obese adolescents (risk of subcutaneous rather than intramuscular injection) 4, 5

Adjunctive Treatments

  • After epinephrine administration, diphenhydramine 1-2 mg/kg or 25-50 mg/dose parenterally may be given 1
  • Consider ranitidine 1 mg/kg intravenously for additional histamine blockade 1
  • For bronchospasm resistant to epinephrine, nebulized albuterol 2.5-5 mg in 3 mL saline may be used 1

Remember that while promethazine (Avil) may have a role in managing allergic reactions, it is not the first-line treatment for anaphylaxis and should never replace epinephrine in the management of anaphylaxis.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Anaphylaxis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

CSACI position statement: epinephrine auto-injectors and children < 15 kg.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2015

Research

Do epinephrine auto-injectors have an unsuitable needle length in children and adolescents at risk for anaphylaxis from food allergy?

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2016

Research

Epinephrine, auto-injectors, and anaphylaxis: Challenges of dose, depth, and device.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.